The Revue Francaise d'Allergologie, an esteemed publication in the field of Immunology and Allergy, is published by ELSEVIER MASSON, CORP OFF in France. This journal plays a pivotal role in disseminating significant findings and advancements in allergy research and immunotherapy, reflecting the latest trends and challenges in these rapidly evolving areas. As part of its commitment to scholarly rigor, the journal encompasses a wide range of topics pertinent to allergology, aiming to bridge the gap between clinical practice and academic research. Although currently not listed as open access, it provides critical insights essential for researchers, professionals, and students alike, ensuring the advancement of knowledge and therapeutic strategies in allergy and immunology. With its impact factor and positioning in the Q4 category, it serves as a valuable resource, aiding in the education and development of future leaders in the field. The Revue Francaise d'Allergologie continues to be a vital platform for the exchange of innovative ideas and findings from 2009 to the present.

The Journal of Allergy and Clinical Immunology-In Practice, published by ELSEVIER, stands as a leading platform in the field of allergy and immunology, specifically tailored for practitioners and researchers. With an impressive 2023 Q1 ranking in both the Immunology and Allergy categories, this journal demonstrates a significant impact within the academic community, evidenced by its Scopus rank #41 out of 233 and an impressive percentile rank of 82. The journal focuses on providing advanced studies, clinical findings, and innovative treatment methodologies that address current challenges in allergy and immunology, making it a vital resource for professionals in these fields. With a comprehensive coverage of relevant topics from 2013 to 2024, the journal continues to evolve alongside emerging trends and developments in clinical practice, fostering an environment conducive to scholarly research and application. Although it currently does not offer open access, authors and readers can access a wealth of information and contribute to ongoing dialogues through its robust publication platform.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, published by MOSBY-ELSEVIER, stands as a leading peer-reviewed journal dedicated to advancing the understanding of allergies and immunological conditions. With a notable impact factor and a prominent stature in the academic community, it ranks in the Q1 category for both Immunology and Allergy in 2023, reflecting its significance and high citation rates among researchers. Since its establishment in 1963, the journal has fostered scientific discourse and innovation in the field, positioning itself as an essential resource for both seasoned professionals and emerging scholars. The Scopus rankings underscore its influence, being ranked 12th out of 233 in Immunology and Allergy and 15th out of 236 in Immunology and Microbiology, placing it in the top centile of both categories. The journal aims to disseminate cutting-edge research, reviews, and clinical studies that deepen our understanding of allergic diseases and enhance patient care. While not an open access journal, it provides institutions and individuals with opportunities to stay informed on crucial advancements in the immunological sciences.

ALLERGOLOGIE is a prominent academic journal dedicated to the field of immunology and allergy, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany. Since its inception in 1978, the journal has provided a vital platform for researchers, clinicians, and students to disseminate their findings, share insights, and foster advancements in the understanding of allergic diseases and immunological responses. With an ISSN of 0344-5062 and an E-ISSN of the same number, it is a respected source within its category, currently ranked in the 2023 Q4 of the Scopus metrics in immunology and allergy, reflecting its commitment to quality and scholarly rigor. Although not fully open access, ALLERGOLOGIE makes significant contributions to the dialogue on allergy-related topics, encouraging engagement from its readership through a diverse array of articles that span from clinical trials to innovative research methods. This journal continues to be an essential resource for anyone involved in the pursuit of knowledge in allergy and immunology.

Asia Pacific Allergy, published by Lippincott Williams & Wilkins, is a prominent academic journal dedicated to advancing research and clinical practice in the fields of dermatology, immunology, and allergy. With its ISSN 2233-8276 and E-ISSN 2233-8268, the journal provides a platform for innovative studies and reviews that cater to an international audience of researchers, healthcare professionals, and students involved in allergy and related disorders. Although it does not currently offer open access to its publications, the journal's robust output from 2015 to 2017 and its ongoing contribution to the literature from 2021 to 2024 showcase the evolving landscape of allergy research in the Asia Pacific region. Recognized in the 2023 Journal Citation Reports, it holds a Q2 ranking in Dermatology and a Q3 ranking in Immunology and Allergy, while its Scopus ranks further emphasize its significance within these domains, positioning it among the top journals in the field. As a source of cutting-edge research, Asia Pacific Allergy plays a vital role in fostering collaboration and knowledge dissemination, ultimately assisting in the betterment of patient care and treatment strategies across the region.

Dermatology Reports is a reputable open-access journal dedicated to advancing the field of dermatology through innovative research and clinical studies. Published by PAGEPRESS PUBL, this journal has been providing unrestricted access to valuable scientific content since 2009, promoting the dissemination of cutting-edge knowledge among researchers, professionals, and students alike. With an ISSN of 2036-7392 and an E-ISSN of 2036-7406, Dermatology Reports is indexed in Scopus, currently holding a rank of 93/142 in the Medicine - Dermatology category, placing it in the 34th percentile. The journal, based in Italy at MEDITGROUP, VIA G BELLI, 4, PAVIA 27100, aims to foster a multidisciplinary approach to dermatological research and practice, with a vision to converge various aspects of the field from 2010 to 2024 and beyond. With its Q3 quartile ranking in 2023, Dermatology Reports stands as a critical platform for highlighting novel findings and therapeutic strategies that shape the future of dermatological science.

Current Opinion in Allergy and Clinical Immunology, published by Lippincott Williams & Wilkins, is a pivotal journal that serves as a key resource for professionals in the fields of immunology and allergy. With an ISSN of 1528-4050 and an E-ISSN of 1473-6322, this journal presents cutting-edge reviews of the latest research findings, methodologies, and therapeutic approaches in the management of allergic and immunological disorders. With a Q3 category ranking in both Immunology and Allergy for 2023, and a Scopus rank of #103 in Immunology and Allergy, it reflects a solid position within the scientific community. Operating in the highly dynamic fields of immunology and clinical practice since its inception in 2001, the journal aims to harmonize emerging research trends with clinical applications to enhance patient outcomes. Although it does not currently offer Open Access options, the journal's substantial impact factor attests to its significance as a scholarly resource. By disseminating high-quality reviews and expert opinions, Current Opinion in Allergy and Clinical Immunology continues to foster knowledge advancement and professional development among researchers, practitioners, and students alike.

Allergy Asthma and Clinical Immunology, a pioneering open access journal published by BMC, has been at the forefront of immunological research since its inception in 2005. With an ISSN of 1710-1492, this UK-based journal has established a significant presence in the fields of Immunology, Allergy, and Pulmonary and Respiratory Medicine, achieving notable quartile rankings such as Q2 in Immunology and Allergy in 2023. It plays a crucial role in disseminating high-quality research that advances our understanding of allergy and asthma, making substantial contributions to clinical practices and public health. The journal embraces the principles of Open Access, allowing researchers, professionals, and students from around the globe to access its content freely, thus facilitating knowledge sharing and collaboration within the scientific community. As it converges towards 2024, Allergy Asthma and Clinical Immunology continues to attract impactful studies that drive innovation and improve patient care in the face of rapidly evolving challenges in immunological health.

Welcome to the Allergo Journal, a pivotal publication in the field of Immunology and Allergy, housed under the esteemed SPRINGER HEIDELBERG publishing house. With an ISSN of 0941-8849 and E-ISSN 2195-6405, the journal has been serving the scientific community since its inception in 1994. Although its Scopus coverage was discontinued in 2017, the journal remains significant, ranked #135 out of 186 in its category and positioned in the 27th percentile, reflecting its contributions to vital research in allergy and immunological disorders. While the journal is not an open access publication, it continues to provide a platform for rigorous academic discourse and advances in the study of allergens and immune response. The Allergo Journal stands as a crucial resource for researchers, professionals, and students dedicated to deepening their understanding of allergies and immunology, fostering advancements in therapy and comprehensive patient care.

CLINICAL AND EXPERIMENTAL ALLERGY is a premier peer-reviewed journal dedicated to advancing the scientific understanding of allergy and immunology. Published by Wiley in the United Kingdom, this esteemed journal maintains a significant impact factor, reflecting its high standards and influential research contributions. With an impressive history since its inception in 1971, the journal is poised to continue leading the discourse in the field until at least 2024. It is ranked in the Q2 quartile for both Immunology and Allergy categories, further highlighting its reputable standing within the academic community. The journal's Scopus rankings showcase its academic relevance, securing the 49th and 51st positions in the Medicine and Immunology categories, respectively. Researchers, professionals, and students will find vital insights and contemporary research trends within its pages, making it an essential resource for those invested in understanding and addressing allergic diseases and disorders.